Patents Assigned to THE INSTITUTE FOR RESEARCH IN BIOMEDICINE
-
Patent number: 8309089Abstract: The invention relates to neutralizing antibodies which are specific for human cytomegalovirus and bind with high affinity as well as immortalized B cells that produce such antibodies. The invention also relates to the epitopes that the antibodies bind to as well as the use of the antibodies and the epitopes in screening methods as well as the diagnosis and therapy of disease.Type: GrantFiled: April 22, 2011Date of Patent: November 13, 2012Assignee: Institute for Research in BiomedicineInventors: Antonio Lanzavecchia, Annalisa Macagno
-
Patent number: 8298538Abstract: The invention relates to neutralizing antibodies and antibody fragments having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for a combination of hCMV proteins UL130 and UL131A, or for a combination of hCMV proteins UL128, UL130 and UL131A. The invention relates also to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis and therapy of disease.Type: GrantFiled: April 15, 2011Date of Patent: October 30, 2012Assignee: Institute for Research in BiomedicineInventors: Antonio Lanzavecchia, Annalisa Macagno
-
Patent number: 8298539Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.Type: GrantFiled: December 28, 2011Date of Patent: October 30, 2012Assignee: Institute for Research in BiomedicineInventors: Antonio Lanzavecchia, Annalisa Macagno
-
Patent number: 8287870Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.Type: GrantFiled: December 28, 2011Date of Patent: October 16, 2012Assignee: Institute for Research in BiomedicineInventors: Antonio Lanzavecchia, Annalisa MacAgno
-
Publication number: 20120128692Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.Type: ApplicationFiled: December 28, 2011Publication date: May 24, 2012Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINEInventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
-
Publication number: 20120128691Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.Type: ApplicationFiled: December 28, 2011Publication date: May 24, 2012Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINEInventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
-
Publication number: 20120114664Abstract: Provided are human antibodies that can neutralize a H5N1 strain of influenza A virus. Also provided are antibodies that can neutralize a strain of influenza A virus in clade 2 of the H5 subtype, that can neutralize a H5N1 strain of influenza A virus and have a lambda light chain, and that are IgG antibodies (but not with a IgG1 heavy chain) that can neutralize a H5N1 strain of influenza A virus.Type: ApplicationFiled: January 16, 2012Publication date: May 10, 2012Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINEInventor: Antonio Lanzavecchia
-
Patent number: 8124093Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.Type: GrantFiled: July 15, 2009Date of Patent: February 28, 2012Assignee: Institute for Research in BiomedicineInventors: Antonio Lanzavecchia, Annalisa Macagno
-
Patent number: 8124092Abstract: Provided are human antibodies that can neutralize a H5N1 strain of influenza A virus. Also provided are antibodies that can neutralize a strain of influenza A virus in clade 2 of the H5 subtype, that can neutralize a H5N1 strain of influenza A virus and have a lambda light chain, and that are IgG antibodies (but not with a IgG1 heavy chain) that can neutralize a H5N1 strain of influenza A virus.Type: GrantFiled: March 13, 2008Date of Patent: February 28, 2012Assignee: Institute for Research in BiomedicineInventor: Antonio Lanzavecchia
-
Publication number: 20120027768Abstract: A method for producing a clone of an immortalised human B memory lymphocyte, comprising the step of transforming human B memory lymphocytes using Epstein Barr virus (EBV) in the presence of a polyclonal B cell activator. The method is particularly useful in a method for producing a clone of an immortalised human B memory lymphocyte capable of producing a human monoclonal antibody with a desired antigen specificity, comprising the steps of: (i) selecting and isolating a human memory B lymphocyte subpopulation; (ii) transforming the subpopulation with Epstein Ban virus (EBV) in the presence of a polyclonal B cell activator; (iii) screening the culture supernatant for antigen specificity; and (iv) isolating an immortalised human B memory lymphocyte clone capable of producing a human monoclonal antibody having the desired antigen specificity.Type: ApplicationFiled: October 17, 2011Publication date: February 2, 2012Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINEInventor: Antonio Lanzavecchia
-
Publication number: 20120020957Abstract: The invention relates to antibodies and antigen binding fragments thereof and to cocktails of antibodies and antigen binding fragments that neutralize dengue virus infection without contributing to antibody-dependent enhancement of dengue virus infection. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antigen binding fragments. In addition, the invention relates to the use of the antibodies, antigen binding fragments, and epitopes in screening methods as well as in the diagnosis and therapy of dengue virus infection.Type: ApplicationFiled: October 13, 2009Publication date: January 26, 2012Applicant: Institute For Research in BiomedicineInventor: Antonio Lanzavecchia
-
Publication number: 20110274702Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that specifically bind to an epitope in the stem region of an influenza A hemagglutinin trimer and neutralize a group 1 subtype and a group 2 subtype of influenza A virus. The invention also relates to nucleic acids that encode, immortalized B cells and cultured single plasma cells that produce, and to epitopes that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, treatment and prevention of influenza A virus infection.Type: ApplicationFiled: July 18, 2011Publication date: November 10, 2011Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINEInventor: Antonio Lanzavecchia
-
Publication number: 20110268746Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.Type: ApplicationFiled: July 15, 2009Publication date: November 3, 2011Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINEInventors: Antonio Lanzavecchia, Annalisa MacAgno
-
Publication number: 20110159001Abstract: This invention relates generally to human monoclonal antibodies against SARS-CoV, epitopes bound by the bodies as well as to methods for use thereof.Type: ApplicationFiled: January 16, 2009Publication date: June 30, 2011Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINEInventor: Antonio Lanzavecchia
-
Publication number: 20100278834Abstract: Provided are human antibodies that can neutralize a H5N1 strain of influenza A virus. Also provided are antibodies that can neutralize a strain of influenza A virus in clade 2 of the H5 subtype, that can neutralize a H5N1 strain of influenza A virus and have a lambda light chain, and that are IgG antibodies (but not with a IgG1 heavy chain) that can neutralize a H5N1 strain of influenza A virus.Type: ApplicationFiled: March 13, 2008Publication date: November 4, 2010Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINEInventor: Antonio Lanzavecchia
-
Publication number: 20100145031Abstract: The invention relates to methods of producing antibodies, including monoclonal antibodies, comprising culturing a limited number of plasma cells. It also relates to methods of identifying antibodies by performing assays on the antibodies produced by the cultured plasma cells to determine their function, binding specificity, epitope specificity, and/or their ability to neutralize a toxin or a pathogen. The invention also relates to antibodies and antibody fragments produced by the methods of the invention as well as methods of using the antibodies and antibody fragments.Type: ApplicationFiled: October 22, 2009Publication date: June 10, 2010Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINEInventors: Antonio Lanzavecchia, David Jarrossay
-
Publication number: 20100092481Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.Type: ApplicationFiled: July 15, 2009Publication date: April 15, 2010Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINEInventors: Antonio Lanzavecchia, Annalisa Macagno
-
Publication number: 20100086555Abstract: The invention relates to antibodies and antigen binding fragments thereof, that bind to hemagglutinin and neutralize infection of at least two different group 1 subtypes or at least two different group 2 subtypes of influenza A virus. The invention also relates to nucleic acids that encode, immortalized B cells and cultured single plasma cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, treatment and prevention of influenza A virus infection.Type: ApplicationFiled: July 27, 2009Publication date: April 8, 2010Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINEInventor: Antonio Lanzavecchia
-
Publication number: 20100080813Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that bind to hemagglutinin and neutralize a group 1 subtype and a group 2 subtype of influenza A virus. The invention also relates to nucleic acids that encode, immortalized B cells and cultured single plasma cells that produce, and to epitopes that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, treatment and prevention of influenza A virus infection.Type: ApplicationFiled: July 27, 2009Publication date: April 1, 2010Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINEInventor: Antonio Lanzavecchia
-
Publication number: 20100021470Abstract: A method for producing a clone of an immortalised human B memory lymphocyte, comprising the step of transforming human B memory lymphocytes using Epstein Barr Virus (EBV) in the presence of a polyclonal B cell activator. The method is particularly useful in a method for producing a clone of an immortalised human B memory lymphocyte capable of producing a human monoclonal antibody with a desired antigen specificity, comprising the steps of: (i) selecting and isolating a human memory B lymphocyte subpopulation; (ii) transforming the subpopulation with Epstein Barr Virus (EBV) in the presence of a polyclonal B cell activator; (iii) screening the culture supernatant for antigen specificity; and (iv) isolating an immortalised human B memory lymphocyte clone capable of producing a human monoclonal antibody having the desired antigen specificity.Type: ApplicationFiled: February 26, 2004Publication date: January 28, 2010Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINEInventor: Antonio Lanzavecchia